Table 1.

Baseline characteristics of patients on opioid agonist therapy in Norway

Baseline characteristics	2013		2014		2015		2016		2017
	No.	%	No.	%	No.	%	No.	%	No.	%
Patients	7709		7914		7958		7804		7709
Deaths	165		151		138		114		124
Patients, excl. deaths	7544		7763		7820		7690		7585
Age
- ≤ 25	211	3	185	2	171	2	135	2	120	2
- 26-35	1590	21	1570	20	1551	20	1403	18	1333	18
- 36-45	2724	36	2730	35	2605	33	2508	33	3292	32
- 46-55	2283	30	2449	32	2544	33	2540	33	2548	34
- ≥ 56	736	10	829	11	949	12	1104	14	1192	16
Mean (SD)	43 (10)		44 (10)		44 (10)		44 (10)		45 (10)
Gender
Men	5221	69	5390	69	5430	69	5354	70	5245	69
Women	2323	31	2373	31	2390	31	2336	30	2340	31
OAT opioidsa
Methadone, included levomethadone	3406	45	3264	42	3216	41	3066	40	2981	39
Buprenorphineb	4138	55	4499	58	4604	59	4624	60	4604	61
Potentially addictive drugs
Dispensed a benzodiazepine and z-hypnoticc	3747	50	3809	49	3714	47	3758	49	3762	50
Dispensed a gabapentinoid	708	9	662	9	717	9	762	10	845	11

NorPD Norwegian Prescription Database, OAT Opioid agonist therapy, SD Standard deviation

^aThe last type of dispensed OAT opioid per year

^bInclude buprenorphine-naloxone

^cZ-hypnotic includes zolpiclone and zolpidem